liver tumors: RFA-for small liver tumors-3 cm. or smaller-is superior to ethanol injections emerges from randomized study. Article update 5 August 2011
22 september 2005: source: Gastroenterology. 2005 Jul; 129 (1): 122-30.RFA-Radio Frequency Ablation is superior to ethanol injections at small liver tumors-3 cm. diameter or smaller-shows off new randomized study. Median survival time was 74% for the 4 year group over 57% of the ethanol group RFA. See below the translated results of this study.
Thanks to CVZ = College of health insurers who write in an accompanying letter about the compensation duty for beside their RFA and TACE and LITT a.o. this study abstract mention. Incidentally, the list of studies is next to the letter that 25 A-6 A-pages long pages long and which describes how CVZ has done research and come to the conclusion that RFA, and TACE for liver tumors, LITT usual treatments are uitzaaiïngen of other kannkersoorten such as bv also primary. breast cancer and bowel cancers and be reimbursed under certain conditions reasonable companies. Whom a copy of the letter from the study abstract about RFA, CVZ plus and want to have that can make requests to TACE LITT editorial cancer-current .nl. We charge € 15,--for postage and shipping costs. Get discount and OPS members pay € 7.50 for studieabstracten plus a copy of the letter. Here the results as good as literally translated the study which compared the effect of RFA with ethanol injections.
Results: 118 patients formed the group that RFA = Radio Frequency Ablation treatment and 114 patients received an ethanol were as injection. The number of treatment sessions with RFA was less (2.1 times vs. 6.4 times, respectieveljik, P< .0001)="" en="" de="" lengte="" van="" de="" ziekenhuisopname="" was="" korter="" (10.8="" dagen="" vs="" 26.1="" dagen,="" respectievelijk,="" p="">< .0001)="" bij="" de="" rfa="" patiëntengroep="" dan="" bij="" de="" ethanol="" injectie="" patiëntengroep.="" mediane="" 4-jaars="" overleving="" was="" 74%="" (95%="" ci:="" 65%-84%)="" in="" de="" rfa="" groep="" en="" 57%="" (95%="" ci:="" 45%-71%)="" in="" de="" ethanol="" injectie="" groep.="" rfa="" gaf="" 46%="" minder="" risico="" op="" sterfte(adjusted="" relative="" risk,="" 0.54="" [95%="" ci:="" 0.33-0.89],="" p=".02)," een="" 43%="" minder="" risico="" op="" een="" overall="" recidief(adjusted="" relative="" risk="" 0.57="" [95%="" ci:="" 0.41-0.80],="" p=".0009)," en="" een="" 88%="" kleiner="" risico="" op="" locale="" tumor="" progressie="" (relative="" risk,="" 0.12="" [95%="" ci:="" 0.03-0.55],="" p=".006)" dan="" bij="" een="" ethanol="" injectie="" behandeling.="" in="" het="" optreden="" van="" ernstige="" bijwerkingen="" was="" geen="" verschil="" tussen="" beide="">
Conclusions: Weighing from longer survival but with same pattern is RFA-Radio Frequency Ablation side effects superior to an ethanol injection treatment of small liver tumors.
Gastroenterology. 2005 Jul; 129 (1): 122-30
A randomized controlled trial or radiofrequency ablation with ethanolinjection for small hepatocellular carcinoma.
Shiina S, T, S, Sato S, Teratani Obi Fujishima T, Ishikawa T, Tateishi R, Y, Yoshida H, Koike T Kawabe, M. Omata
Department of Gastroenterology, University of Tokyo, Japan. sshiina-tky@umin.ac.jp
Percutaneous radiofrequency ablation is a & BACKGROUND AIMS: treatment for hepatocellular carcinoma, whereas recently introduced is now a standard ethanol injection therapy. We compared their long-term outcomes.
METHODS: Two hundred thirty-two patients with hepatocellular carcinoma who had 3 or fewer lesions, each 3 cm or less in diameter, and liver function or Child-Pugh class A or B were entered onto a randomized controlled trial. The primary end point was survival, and the secondary end points were overall recurrence and local tumor progression.
RESULTS: One hundred eighteen patients were assigned to radiofrequency ablation and ethanol injection to 114. The number of treatment sessions was narrower (2.1 times vs. 6.4 times, respectively, P< .0001)="" and="" the="" length="" of="" hospitalization="" was="" shorter="" (10.8="" days="" vs="" 26.1="" days,="" respectively,="" p="">< .0001)="" in="" radiofrequency="" ablation="" than="" in="" ethanol="" injection.="" four-year="" survival="" rate="" was="" 74%="" (95%="" ci:="" 65%-84%)="" in="" radiofrequency="" ablation="" and="" 57%="" (95%="" ci:="" 45%-71%)="" in="" ethanol="" injection.="" radiofrequency="" ablation="" had="" a="" 46%="" smaller="" risk="" of="" death="" (adjusted="" relative="" risk,="" 0.54="" [95%="" ci:="" 0.33-0.89],="" p=".02)," a="" 43%="" smaller="" risk="" of="" overall="" recurrence="" (adjusted="" relative="" risk="" 0.57="" [95%="" ci:="" 0.41-0.80],="" p=".0009)," and="" an="" 88%="" smaller="" risk="" of="" local="" tumor="" progression="" (relative="" risk,="" 0.12="" [95%="" ci:="" 0.03-0.55],="" p=".006)" than="" ethanol="" injection.="" the="" incidence="" of="" adverse="" events="" was="" not="" different="" between="" the="" 2="">
CONCLUSIONS: Judging from higher survival but similar adverse events, radiofrequency ablation for hepatocellular carcinoma is superior to ethanol injection small.
PMID: 16012942 [PubMed-in process]
